In contrast, in similar experiments performed in the KRAS-dependent A549 cell line, neither MSI2 depletion, erlotinib treatment, nor the combination significantly impaired tumor growth (Supp Fig. S10A, B). This evidence concerns the gene KRAS and neoplasm.